Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 16:2020:8895968.
doi: 10.1155/2020/8895968. eCollection 2020.

Analysis of Long Noncoding RNA ZNF667-AS1 as a Potential Biomarker for Diagnosis and Prognosis of Glioma Patients

Qin Yuan  1 , Chao Gao  2 , Xiao-Dong Lai  3 , Liang-Yi Chen  4 , Tian-Bao Lai  4
Affiliations

Analysis of Long Noncoding RNA ZNF667-AS1 as a Potential Biomarker for Diagnosis and Prognosis of Glioma Patients

Qin Yuan et al. Dis Markers. .

Abstract

Objective: Long noncoding RNAs (lncRNAs) have been strongly associated with various types of cancer. The present study aimed at exploring the diagnostic and prognostic value of lncRNA Zinc finger protein 667-antisense RNA 1 (ZNF667-AS1) in glioma patients. Patients and Methods. The expressions of ZNF667-AS1 were detected in 155 glioma tissues and matched normal brain tissue samples by qRT-PCR. The receiver operating characteristic (ROC) curve was performed to estimate the diagnostic value of ZNF667-AS1. The association between the ZNF667-AS1 expression and clinicopathological characteristics was analyzed by the chi-square test. The Kaplan-Meier method was performed to determine the influence of the ZNF667-AS1 expression on the overall survival and disease-free survival of glioma patients. The Cox regression analysis was used to evaluate the effect of independent prognostic factors on survival outcome. Cell proliferation was measured by the respective cell counting Kit-8 (CCK-8) assays.

Results: We observed that ZNF667-AS1 was significantly upregulated in glioma tissues compared to normal tissue samples (p < 0.01). Higher levels of ZNF667-AS1 were positively associated with the WHO grade (p = 0.018) and KPS score (p = 0.008). ROC assays revealed that the high ZNF667-AS1 expression had an AUC value of 0.8541 (95% CI: 0.8148 to 0.8934) for glioma. Survival data revealed that glioma patients in the high ZNF667-AS1 expression group had significantly shorter 5-year overall survival (p = 0.0026) and disease-free survival (p = 0.0005) time than those in the low ZNF667-AS1 expression group. Moreover, multivariate analyses confirmed that the ZNF667-AS1 expression was an independent predictor of the overall survival and disease-free survival for glioma patients. Functionally, we found that knockdown of ZNF667-AS1 suppressed the proliferation of glioma cells.

Conclusions: Our results suggest that ZNF667-AS1 could be used as a potential diagnostic and prognostic biomarker in glioma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart in the selection of study patients.
Figure 2
Figure 2
The ZNF667-AS1 expression is increased in glioma tissues. (a) The relative expression of ZNF667-AS1 in paired tumor and nontumor tissues (n = 155) by RT-PCR. The expression of ZNF667-AS1 in different tumor grades.
Figure 3
Figure 3
ZNF667-AS1 may be a potential diagnostic biomarker for glioma patients. (a) The ROC curve for the diagnostic value of ZNF667-AS1 in distinguishing glioma specimens from nontumor brain specimens. (b) The ROC curve for the diagnostic value of ZNF667-AS1 in distinguishing glioma specimens with stages (I-II) from glioma specimens with stages (III-IV).
Figure 4
Figure 4
Kaplan-Meier curves of the overall survival (a) and disease-free survival (b) of 155 glioma patients.
Figure 5
Figure 5
Knockdown of ZNF667-AS1 silencing inhibits the proliferation of A172 and LN118 cells. (a) RT-PCR for the demonstration of the ZNF667-AS1 expression in five glioma cells and NHA. (b) qPCR analyses of ZNF667-AS1 levels following treatment of A172 and LN118 cells with si-ZNF667-AS1-1, ZNF667-AS1-2, or si-NC. (c, d) The MTT assay was performed to determine the proliferation of A172 and LN118. ∗∗p < 0.05.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ostrom Q. T., Bauchet L., Davis F. G., et al. The epidemiology of glioma in adults: a "state of the science" review. Neuro-Oncology. 2014;16(7):896–913. doi: 10.1093/neuonc/nou087. - DOI - PMC - PubMed
    1. Grimm S. A., Chamberlain M. C. Brainstem glioma: a review. Current Neurology and Neuroscience Reports. 2013;13(5) doi: 10.1007/s11910-013-0346-3. - DOI - PubMed
    1. Chen R., Smith-Cohn M., Cohen A. L., Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017;14(2):284–297. doi: 10.1007/s13311-017-0519-x. - DOI - PMC - PubMed
    1. Bush N. A., Chang S. M., Berger M. S. Current and future strategies for treatment of glioma. Neurosurgical Review. 2017;40(1):1–14. doi: 10.1007/s10143-016-0709-8. - DOI - PubMed
    1. Hervey-Jumper S. L., Berger M. S. Insular glioma surgery: an evolution of thought and practice. Journal of Neurosurgery. 2019;130(1):9–16. doi: 10.3171/2018.10.JNS181519. - DOI - PubMed

LinkOut - more resources